Foghorn Therapeutics (FHTX) Earnings Date & Reports

Key Takeaways

• Foghorn Therapeutics reported a third-quarter 2025 net loss of $15.85 million, improving from $19.12 million in the same period a year earlier.
• Loss per share came in at $0.25, narrower than the consensus estimate of a $0.31 loss.
• Collaboration revenue of $8.15 million exceeded the roughly $6.20 million consensus estimate, up from $7.81 million a year ago.
• Operating expenses fell about 15.8% year over year, driven by the discontinuation of independent FHD-286 development and reduced facility costs.
• The company ended the quarter with roughly $180.3 million in cash and marketable securities, extending its projected runway into 2028.

Earnings Context and Why It Matters

Foghorn Therapeutics is a clinical-stage biopharmaceutical company focused on medicines that target the chromatin regulatory system, which controls how genes are turned on and off. For a development-stage company without product sales, quarterly results matter less for top-line performance and more for two things: disciplined spending and pipeline execution. This report arrives as the company concentrates its resources on FHD-909, a drug candidate being advanced in partnership with Eli Lilly, while stepping back from independent FHD-286 development. Investors are watching whether the narrower focus can stretch cash reserves and generate meaningful clinical catalysts.

Reported Results

For the quarter ended September 30, 2025, Foghorn Therapeutics reported a net loss of $15.85 million, compared with $19.12 million in the year-ago quarter. Basic and diluted loss per share (EPS, meaning net loss divided by shares outstanding) was $0.25, versus $0.31 a year earlier and narrower than the consensus estimate of a $0.31 loss.

Collaboration revenue, which reflects the recognition of the upfront payment under the company's Eli Lilly agreement, totaled $8.15 million, up from $7.81 million a year ago and above the approximately $6.20 million consensus forecast. Total operating expenses declined roughly 15.8% to $26.65 million, largely reflecting lower research and development (R&D) costs after the discontinuation of independent FHD-286 development and savings from a June 2025 lease modification.

As of September 30, 2025, the company reported cash and cash equivalents of $89.33 million plus $90.94 million in marketable securities, for combined liquidity of about $180.3 million. Management has indicated this is sufficient to fund operations into 2028. The quarter also brought a leadership change, with Chief Financial Officer (CFO) Kristian Humer announcing his resignation effective November 14, 2025.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For earnings-focused investors, the screener can help surface trending stocks, breakout candidates, and emerging trade ideas more efficiently than manual screening. Explore the AI Screener to identify opportunities that match your own research criteria.

Market Reaction and Investor Sentiment

The top- and bottom-line beats gave investors a modest positive signal, but for a clinical-stage biotech, the market's longer-term focus remains on pipeline catalysts and cash durability rather than a single quarter's expense management. The stock has underperformed the broader market over the past year, reflecting the typical discount applied to pre-revenue drug developers.

Two items likely tempered enthusiasm: the announced CFO departure just ahead of the report and the reality that reported collaboration revenue stems from an already-booked partnership agreement rather than new commercial activity. Investor interpretation of these results therefore hinges on management's commentary about FHD-909 clinical progress and the timeline for meaningful data readouts.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central narrative for Foghorn Therapeutics is the advancement of FHD-909 under its collaboration with Eli Lilly. Progress through the ongoing Phase 1 dose-escalation study, along with any decisions around dose expansion or additional indications, will be the primary drivers of investor attention in the coming quarters.

On the financial side, investors should monitor whether the company sustains its leaner expense base as FHD-909 enrollment expands. Management has signaled that costs are likely to rise as the study advances, so the trajectory of R&D spending relative to the stated cash runway into 2028 will be a key checkpoint in future reports.

The CFO transition is another factor worth watching. A swift appointment of a successor with capital-markets or biotech-operating experience could reassure investors, while a prolonged vacancy might add execution uncertainty. Finally, any updates on the broader pipeline, including earlier-stage programs and potential new collaboration terms, could reshape the company's long-term outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations